NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the first patient was successfully treated with Actimab-A drug candidate manufactured with the new lot of Lintuzumab, the antibody that provides the backbone for Actimab-A. The ongoing Phase 1/2 trial of Actimab-A is in newly diagnosed AML patients over the age of 60 in a single arm multicenter trial.
Help employers find you! Check out all the jobs and post your resume.
